Loading...
•
Sep 30, 2020
Anavex Q4 2020 Earnings Report
Reported financial results for the fiscal year ended September 30, 2020.
Key Takeaways
Anavex Life Sciences reported its financial results for the fiscal year ended September 30, 2020, highlighting significant progress across its portfolio, including positive trial results for ANAVEX®2-73 in Rett syndrome and Parkinson's disease dementia.
Positive, placebo-controlled, U.S. ANAVEX®2-73 (blarcamesine) Rett syndrome trial.
Positive Parkinson’s disease dementia trial.
Further progress in Alzheimer’s disease.
Key milestones expected from multiple programs.
Forward Guidance
Anavex anticipates key milestones from multiple programs.
Positive Outlook
- Data on the ongoing late-stage Rett syndrome trials AVATAR and EXCELLENCE.
- Expanding the clinical biomarker-driven ANAVEX®2-73 rare disease program into additional late-stage studies with high unmet medical need.
- Completing the late stage ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease trial.
- Advancing ANAVEX®2-73 into clinical disease modifying testing in Parkinson’s disease.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...